CG Oncology, Inc. CGON
$59.30
▲ +3.33% 24H
About
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesical…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees142
TickerCGON
Statistics
Market Cap$5.22B
Revenue (TTM)$4.0M
Net Income-$161.0M
Net Margin-3985.0%
EPS$-2.08
P/E-27.72
P/S985.69
P/B4.57
EV/EBITDA-18.48
ROE-20.8%
Dividend Yield—
Price$59.30
Data: Twelve Data · Revenue = mcap / P/S